[This Week's IPO] December Second Week Demand Forecast and Subscription Schedule

In the second week of this month (December), Oncocross, Onconic Therapeutics, ISTE, Duchem Bio, and Three A Logics are preparing for their general subscription offerings.

◆Oncocross= The final offering price was set at 7,300 KRW, below the lower end of the expected price band (10,100~12,300 KRW). The institutional subscription competition rate recorded 635 to 1. The general subscription will take place on the 9th and 10th, with a planned listing on the KOSDAQ market on the 18th. The lead underwriter is Mirae Asset Securities.

Oncocross analyzes drugs in clinical stages through its self-developed AI platform ‘RAPTOR AI’. RAPTOR AI is an AI drug development platform that screens optimal indications for new drug candidates or existing developed drugs.

◆Onconic Therapeutics= The offering price was set at 13,000 KRW, below the lower end of the expected price band (16,000~18,000 KRW). The institutional demand forecast competition rate was 198.96 to 1. General shareholder subscription will be conducted over two days on the 9th and 10th, with a planned listing on the 19th. The lead underwriter is NH Investment & Securities.

Onconic Therapeutics launched and began sales on the 1st of this month of ‘Jacubojeong’, a domestic No. 37 new drug P-CAB (potassium-competitive acid blocker) expected to replace existing PPIs (proton pump inhibitors) in the peptic ulcer drug market.

◆ISTE= The expected offering price range is 9,700~11,400 KRW. Institutional investor demand forecasting was conducted until the 6th, and general subscription will be held over two days on the 10th and 11th. The lead underwriter is KB Securities.

Founded in 2013, ISTE is a specialized company developing and mass-producing semiconductor equipment. It is focusing on future growth by successfully developing PECVD, a core semiconductor process equipment. Based on professional research personnel and national PECVD projects, it succeeded in developing SiCN PECVD equipment in 2021.

◆Duchem Bio= The expected offering price is 12,300~14,100 KRW per share. Institutional investor demand forecasting was conducted until the 6th, and general subscription will be held from the 11th to the 12th. The lead underwriter is NH Investment & Securities.

Duchem Bio holds over 90% market share in the domestic Alzheimer’s dementia diagnostic reagent market. With the upcoming domestic launch of the global dementia new drug Leqembi (developers Eisai and Biogen), expectations for future performance are high.

◆Three A Logics= The expected offering price per share is 15,700~18,200 KRW. Institutional investor demand forecasting will be conducted until the 10th to finalize the offering price, followed by general subscription from the 13th to the 16th, with a planned listing in December. The joint lead underwriters are Mirae Asset Securities and Shinhan Investment Corp.

Since its establishment in 2004, Three A Logics has succeeded in domestic production of NFC-related technology, which had previously relied on overseas products, securing a dominant position in the domestic market. It was the first in Korea to develop NFC Dynamic Tag chips and NFC Reader chips independently, and its ‘TNR100’, which applies the Digital Key 1.0 standard for vehicle digital keys, also became the first in Korea to obtain AEC-Q100 Grade 1 certification from the Automotive Electronics Council (AEC).